Next Generation Sensing for Human in vivo Pharmacology - Accelerating Drug Development in Inflammatory Diseases in collaboration with GSK

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:12 publications

Grant number: EP/S025987/1

Grant search

Key facts

  • Disease

    COVID-19
  • Known Financial Commitments (USD)

    $481,798.73
  • Funder

    UK Research and Innovation (UKRI)
  • Principle Investigator

    Pending
  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    University of Edinburgh
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Led by the University of Edinburgh, Centre for Inflammation Research, the team wish to rapidly instigate, operationalise and deliver a cross-sector, multidisciplinary programme to expedite repurposing of promising pharmaceutical assets with prior use in man for lead prioritisation and evaluation in experimental clinical trials with readiness for global access. The key intervention is to prevent the lung damage in patients with COVID-19 that leads to respiratory failure, therefore reducing the need for MV and saving lives. As part of this strategy, an enabling technology is currently being developed within this EPSRC HIPS award. The goal of the original HIPS grant in collaboration with GSK was to further develop a cutting-edge point-of-care technology platform which would help drug developers, patients, doctors and healthcare workers throughout the world. This platform, KronoScan , was initially intended to be used as an ultra-sensitive microscopic imaging tool in the evaluation of drug action, with a particular focus on drug development for diseases which are characterised by infectious and inflammatory pathway-mediated tissue injury. This additional funding is to urgently expedite the translation/evaluation and use of Kronoscan in the setting of experimental medicine to evaluate novel therapies targeting fulminant respiratory failure due to ARDS.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

A Novel Fit-Flexible Fluorescence Soft Imager: Tri-Sensing of Intensity, Fall-Time, and Life Profile.

Specific in situ immuno-imaging of pulmonary-resident memory lymphocytes in human lungs.

Deep learning-assisted co-registration of full-spectral autofluorescence lifetime microscopic images with H&E-stained histology images.

Fast and Robust Single-Exponential Decay Recovery From Noisy Fluorescence Lifetime Imaging.

Phototherapeutic Induction of Immunogenic Cell Death and CD8+ T Cell-Granzyme B Mediated Cytolysis in Human Lung Cancer Cells and Organoids.

Fibroblast Activation Protein Specific Optical Imaging in Non-Small Cell Lung Cancer.

Pulmonary-Resident Memory Lymphocytes: Pivotal Orchestrators of Local Immunity Against Respiratory Infections.

Core crosstalk in ordered imaging fiber bundles.

Solitary pulmonary nodule imaging approaches and the role of optical fibre-based technologies.